Global Life Sciences Brochure 2023
View and download our Global Life Sciences brochure
In today's competitive landscape, innovative leaders in the healthcare and life sciences industries rely on Dechert to navigate their most complex and demanding transactional, intellectual property and litigation matters anywhere in the world.
We represent clients through all stages of the product life cycle – from discovery through development, clinical testing, promotion and sales. We draw on our antitrust, corporate, dispute resolution (litigation and arbitration) intellectual property, product liability, securities, tax and white collar defense, FCPA and corruption investigations lawyers to provide comprehensive solutions to the industry’s most sophisticated challenges.
With dedicated resources deployed at major life sciences hotbeds across the U.S., Europe and Asia, our global team of lawyers collaborates seamlessly to help clients establish or expand their international presence.
Whether guiding a start-up biotech through its first round of commercially significant funding, executing a strategic acquisition for a large pharmaceutical company, licensing a medical device company’s patents or winning antitrust, securities or patent disputes, our lawyers approach every matter with the resources of a major international firm and the focus and depth of a life sciences boutique.
We routinely advise on complex cross-border and domestic transactions. Our clients range from start-ups to multinationals in pharmaceuticals, biotechnology, drug discovery, genomics, diagnostics, medical devices, biosimilars, and digital health – as well as the life sciences industry’s most active investment banks, venture/growth capital firms and research institutions.
Our life sciences transaction lawyers enhance the development and commercialization of new technologies and scientific breakthroughs by negotiating mergers, acquisitions, spin-offs and joint ventures, advising on licensing options, partnerships and strategic alliances, and guiding clients through related antitrust and litigation issues. Our team efficiently delivers value to stakeholders by structuring commercially successful transactions, ensuring swift execution and protecting clients’ interests in all phases of the transaction. We also help clients structure capital to support the development and commercialization process, ranging from early-stage venture financings and strategic equity investments to complex public offerings of equity and debt.
During the planning phase, we work in multidisciplinary teams to analyze legal, tax and regulatory implications and conduct risk assessments. As companies prepare for transition, we, in close collaboration with our clients, facilitate the exploration of strategic alternatives and advise on competitive negotiations. A core aspect of our efforts is to support our clients’ teams in managing the details of closing transactions while simultaneously operating their businesses and advising on a range of integration issues.
We collaborate with Dechert specialists in tax, intellectual property, regulatory, antitrust, real estate, environmental, litigation and labor to provide clients with the full range of advisory expertise they need to get the deal done.
When life sciences disputes arise, our cross-practice litigation team works to preserve clients’ interests, assets and reputations, obtaining successful outcomes in litigation and arbitrations across the globe. Drawing on our antitrust/competition, intellectual property, international arbitration, litigation, product liability, regulatory, securities and white collar defense lawyers, we provide comprehensive advice in the most complex life sciences disputes.
We regularly take on bet-the-company litigation for pharmaceutical, biotechnology and medical device companies. Our deep bench of trial lawyers are lead counsel in many of the most significant cases that challenge the healthcare and life sciences industry.
Dechert’s antitrust lawyers pilot deals through the Federal Trade Commission and European Commission, navigating competition investigations and defending private litigation, including class actions. Our IP practice has a dedicated Hatch-Waxman litigation team with extensive experience in litigating Abbreviated New Drug Application (ANDA) disputes. We defend our clients in product liability and consumer fraud claims of all kinds, drawing on the skills of one of the leading product liability practices in the U.S.
Our lawyers also have extensive experience representing life sciences companies in a broad range of securities litigation matters, including claims arising out of the development, commercialization, sale and marketing of pharmaceutical products. We advocate on behalf of clients in disputes, including in litigation and arbitration, arising out of licensing, collaboration, asset purchase and other agreements. We also advise life sciences companies and their boards, audit committees and executives through complex internal and external investigations and related civil litigation.
From defending branded products against generic challenges and coordinating mass tort defenses to protecting companies and their boards from challenges by shareholders, we guide clients through the entire array of contentious issues that arise in the life sciences sector.
Our intellectual property counseling team advises on strategies that achieve life sciences clients’ business goals while balancing risk through all stages of the product life cycle. Working alongside start-ups and multinationals in pharmaceuticals, biotechnology and drug discovery – as well as the industry’s most active venture/growth capital firms and research institutions that fund them – we help clients assess business opportunities, avoid regulatory problems and keep their business momentum energetic and on track.
Recognizing the dual imperative of maximizing patent portfolio value and aggressively protecting client products worldwide, we strive to enhance our clients’ value and afford them the strongest protection. Our services include strategic portfolio management and patent prosecution, IP due diligence associated with M&A deals, joint ventures and other commercial transactions, and post-grant and ex parte proceedings, including interferences, inter partes reviews, opinions, re-examinations, re-issues and oppositions.
Many members of our team hold a Ph.D. or other advanced degrees in the sciences and have either postdoctoral or industrial experience above and beyond their experience as lawyers, enhancing collaboration with our clients’ scientists, executives and legal teams.